Item Type | Name |
Concept
|
Acute Disease
|
Concept
|
Autoimmune Diseases
|
Concept
|
Gastrointestinal Diseases
|
Concept
|
Colonic Diseases
|
Concept
|
Communicable Diseases
|
Concept
|
Crohn Disease
|
Concept
|
Chronic Disease
|
Concept
|
Digestive System Diseases
|
Concept
|
Heart Diseases
|
Concept
|
Ileal Diseases
|
Concept
|
Lung Diseases
|
Concept
|
Nervous System Diseases
|
Concept
|
Peripheral Nervous System Diseases
|
Concept
|
Disease Management
|
Concept
|
Inflammatory Bowel Diseases
|
Concept
|
Disease Progression
|
Academic Article
|
Advances in the management of Crohn's disease: economic and clinical potential of infliximab.
|
Academic Article
|
The cost of hospitalization in Crohn's disease.
|
Academic Article
|
Efficacy of parenteral methotrexate in refractory Crohn's disease.
|
Academic Article
|
Infliximab in Crohn's disease: first anniversary clinical experience.
|
Academic Article
|
The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease.
|
Academic Article
|
First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange.
|
Academic Article
|
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
|
Academic Article
|
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
|
Academic Article
|
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
Academic Article
|
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
|
Academic Article
|
Assessment of variables associated with smoking cessation in Crohn's disease.
|
Academic Article
|
Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy".
|
Academic Article
|
The quality of life in patients with Crohn's disease.
|
Academic Article
|
Mesalamine delivery systems: do they really make much difference?
|
Academic Article
|
Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
|
Academic Article
|
Sperm, sex, and 6-MP: the perception on conception.
|
Academic Article
|
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
|
Academic Article
|
Validation of health-related quality of life instruments.
|
Academic Article
|
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
|
Academic Article
|
The cost of Crohn's disease: drugs or surgery?
|
Academic Article
|
Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002.
|
Academic Article
|
Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies.
|
Academic Article
|
Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
|
Academic Article
|
Endoscopy in inflammatory bowel disease.
|
Academic Article
|
Endoscopy of the small bowel in inflammatory bowel disease.
|
Academic Article
|
Postoperative management of ulcerative colitis and Crohn's disease.
|
Academic Article
|
Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment.
|
Academic Article
|
MLN-02 in IBD: is "super-selective" really super?
|
Academic Article
|
Infliximab decreases resource use among patients with Crohn's disease.
|
Academic Article
|
Methotrexate in IBD--move over 6-MP? Not so fast...
|
Academic Article
|
Infliximab at 5 years--tweaking the recipe for success?
|
Academic Article
|
How should we treat severe acute steroid-refractory ulcerative colitis?
|
Academic Article
|
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
|
Academic Article
|
The pharmacoeconomics of biologic therapy for IBD.
|
Academic Article
|
Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002.
|
Academic Article
|
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
|
Academic Article
|
Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease.
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
Academic Article
|
Infliximab as first-line therapy for severe Crohn's disease?
|
Academic Article
|
Crohn's disease and Takayasu's arteritis.
|
Academic Article
|
Cost utility of initial medical management for Crohn's disease perianal fistula.
|
Academic Article
|
IBD indirect costs: the sleeping giant?
|
Academic Article
|
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
|
Academic Article
|
Economics of the use of biologics in the treatment of inflammatory bowel disease.
|
Academic Article
|
Optimizing conventional therapy for inflammatory bowel disease.
|
Academic Article
|
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
Academic Article
|
IBD: the drugs work...but do the patients?
|
Academic Article
|
The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies.
|
Academic Article
|
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
|
Academic Article
|
Dietary fiber intake and Crohn's disease.
|
Academic Article
|
Ulcerative Colitis Care Pathway.
|
Academic Article
|
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
|
Academic Article
|
Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia.
|
Academic Article
|
Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease.
|
Academic Article
|
What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients.
|
Academic Article
|
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
|
Academic Article
|
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
|
Academic Article
|
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.
|
Academic Article
|
Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease.
|
Academic Article
|
Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.
|
Academic Article
|
A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease.
|
Academic Article
|
Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.
|
Academic Article
|
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
|
Academic Article
|
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
|
Academic Article
|
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.
|
Academic Article
|
Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.
|
Academic Article
|
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease.
|
Academic Article
|
Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease.
|
Academic Article
|
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
|
Academic Article
|
The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response.
|
Academic Article
|
Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia.
|
Academic Article
|
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-a4ß7 and anti-PD1 antibodies.
|
Academic Article
|
Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study.
|
Academic Article
|
Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease.
|
Academic Article
|
Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
|
Academic Article
|
Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe.
|
Academic Article
|
Maneuvering Clinical Pathways for Crohn's Disease.
|
Academic Article
|
Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
|
Academic Article
|
Sex differentials in morbidity and mortality risks examined by age and cause in the same cohort.
|
Academic Article
|
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
|
Academic Article
|
Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.
|
Academic Article
|
Clinical features, prognosis, and response to treatment in polyarteritis.
|
Academic Article
|
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
|
Academic Article
|
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers.
|
Academic Article
|
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
|
Academic Article
|
Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis.
|
Academic Article
|
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
|
Academic Article
|
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
|
Academic Article
|
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease.
|
Academic Article
|
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.
|
Academic Article
|
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
|
Academic Article
|
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?
|
Academic Article
|
Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location.
|
Academic Article
|
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
|
Academic Article
|
Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes.
|
Academic Article
|
The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease.
|
Academic Article
|
Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: a systematic review.
|
Academic Article
|
Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease.
|
Academic Article
|
Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease.
|
Academic Article
|
Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.
|
Academic Article
|
Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis.
|
Academic Article
|
Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis.
|
Academic Article
|
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.
|
Academic Article
|
Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis.
|
Academic Article
|
Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes.
|
Academic Article
|
Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease.
|
Academic Article
|
Low Skeletal Muscle Index Adjusted for Body Mass Index Is an Independent Risk Factor for Inflammatory Bowel Disease Surgical Complications.
|
Academic Article
|
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
|
Academic Article
|
Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis.
|
Academic Article
|
Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis.
|
Academic Article
|
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center.
|